Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience-Reference-Cited by-同舟云学术

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience

Published:2017-09-24 Issue:11 Volume:31 Page:e13109
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Ikegami Toru¹^ORCID,Ueda Yoshihide²,Akamatsu Nobuhisa³,Ishiyama Kohei⁴,Goto Ryoichi⁵,Soyama Akihiko⁶,Kuramitsu Kaori⁷,Honda Masaki⁸,Shinoda Masahiro⁹,Yoshizumi Tomoharu¹,Okajima Hideaki¹⁰,Kitagawa Yuko⁹,Inomata Yukihiro⁸,Ku Yonson⁷,Eguchi Susumu⁶,Taketomi Akinobu⁵,Ohdan Hideki⁴,Kokudo Norihiro³,Shimada Mitsuo¹⁰,Yanaga Katsuhiko¹¹,Furukawa Hiroyuki¹²,Uemoto Shinji¹³,Maehara Yoshihiko¹

Affiliation:

1. Department of Surgery and Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

2. Department of Gastroenterology and Hepatology; Graduate School of Medicine; Kyoto University; Kyoto Japan

3. Division of Artificial Organ and Transplantation; Department of Surgery; University of Tokyo; Tokyo Japan

4. Department of Surgery; Graduate School of Biomedical Sciences; Hiroshima University; Hiroshima Japan

5. Department of Gastroenterological Surgery I; Hokkaido University Graduate School of Medicine; Hokkaido Japan

6. Department of Surgery; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan

7. Department of Surgery; Division of Hepato-Biliary-Pancreatic Surgery; Kobe University Graduate School of Medicine; Kobe Japan

8. Department of Transplantation and Pediatric Surgery; Postgraduate School of Medical Science; Kumamoto University; Kumamoto Japan

9. Department of Surgery; Keio University School of Medicine; Tokyo Japan

10. Department of Surgery; University of Tokushima; Tokushima Japan

11. Department of Surgery; School of Medicine; The Jikei University; Tokyo Japan

12. Department of Surgery; Asahikawa Medical University; Asahikawa Japan

13. Department of Surgery; Graduate School of Medicine; Kyoto University; Kyoto Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ctr.13109/fullpdf

Reference19 articles.

1. Natural history of recurrent hepatitis C;Berenguer;Liver Transpl,2002

2. Virus resistance to direct-acting antiviral drugs in interferon-free regimens;Pawlotsky;Gastroenterology,2016

3. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir;McConachie;Expert Rev Clin Pharmacol,2016

4. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial;Mizokami;Lancet Infect Dis,2015

5. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders;Chayama;Hepatology,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of Liver Transplantation Over the Last 2 Decades Based on a Single-Center Experience of 300 Cases;Annals of Transplantation;2023-10-05

2. Analysis of Short-Term and Long-Term Outcomes of Living Donor Liver Transplantation for Patients with a High Model for End-Stage Liver Disease Score;Transplantation Proceedings;2023-05

3. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants;Journal of Clinical Medicine;2021-11-19

4. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients;Virus Research;2021-09

5. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems;Journal of Gastroenterology and Hepatology;2020-07-28